Jefferies raised the firm’s price target on Insulet (PODD) to $375 from $360 and keeps a Buy rating on the shares. The company’s Q2 report came in well ahead of estimates, which led to a guidance raise across the board, the analyst tells investors in a research note. The firm upped estimates on the “outstanding” quarter.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on PODD:
- Insulet’s Strong Financial Performance and Growth Potential Justify Buy Rating
- Early notable gainers among liquid option names on August 7th
- Morning Movers: Apple adds to yesterday’s gains, Trump calls out Intel CEO
- Insulet up 13% at $313.45 after Q2 earnings beat and guidance raise
- Insulet reports Q2 adjusted EPS $1.17, consensus 92c